D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 118.5 SEK 3.04% Market Closed
Market Cap: 2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Other Long-Term Assets
kr20.6m
CAGR 3-Years
65%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Other Long-Term Assets
kr6m
CAGR 3-Years
4%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Long-Term Assets
kr231.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Long-Term Assets
kr154m
CAGR 3-Years
108%
CAGR 5-Years
123%
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Long-Term Assets
kr1.1B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Other Long-Term Assets
kr567k
CAGR 3-Years
8%
CAGR 5-Years
25%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
118.6 SEK
Fairly Valued
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Other Long-Term Assets?
Other Long-Term Assets
20.6m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Other Long-Term Assets amounts to 20.6m SEK.

What is Devyser Diagnostics AB's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
65%

Over the last year, the Other Long-Term Assets growth was 13%. The average annual Other Long-Term Assets growth rates for Devyser Diagnostics AB have been 65% over the past three years , 65% over the past five years .

Back to Top